Sandoz Continues Momentum From Omnitrope Decision With Momenta Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Momenta’s characterization technology could facilitate manufacture of follow-on biologics.
You may also be interested in...
Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.
Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.
Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY
In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.